UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

12 Oct 2023

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Read More
9 Oct 2023

UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023

Read More
25 Sep 2023

UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan

Read More
19 Sep 2023

UCB Provides Update on U.S. Regulatory Review of Bimekizumab

Read More
15 Sep 2023

UCB receives CHMP positive opinion of zilucoplan for the treatment of adults with generalized myasthenia gravis in Europe

Read More
31 Aug 2023

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe

© 2007 - 2023 UCB S.A., Belgium. All rights reserved. Last updated on: October, 23, 2023